Angiogenesis inhibitors found within the haemostasis pathway.
Angiogenesis, the development of new blood vessels from the existing vasculature, and haemostasis, the coagulation cascade leading to formation of a clot, are among the most consistent host responses associated with cancer. Importantly, these two pathways interrelate, with blood coagulation and fibrinolysis influencing tumor angiogenesis directly, thereby contributing to tumor growth. Moreover, many endogenous inhibitors of angiogenesis are found within platelets or harboured as cryptic fragments of haemostatic proteins. In this review we outline ways in which angiogenesis is coordinated and regulated by haemostasis in human cancer. Then we detail the experimental and pre-clinical evidence for the ability of many of these endogenous proteins to inhibit tumor angiogenesis and thus their potential to be anti-cancer agents, with particular reference to any clinical trials.
Staton
Carolyn A
CA
Microcirculation Research Group, University of Sheffield Medical School, Sheffield, S10 2RX, UK.
Lewis
Claire E
CE
D020533:Angiogenesis Inhibitors / Q000097:blood / Q000502:physiology*; D000818:Animals; D001777:Blood Coagulation / Q000502:physiology; D001792:Blood Platelets / Q000378:metabolism; D006487:Hemostasis / Q000502:physiology*; D006801:Humans; D008954:Models, Biological; D009389:Neovascularization, Pathologic / Q000097:blood / Q000503:physiopathology; D018919:Neovascularization, Physiologic / Q000502:physiology
D020533:Angiogenesis Inhibitors